Immunother Limited today announced the results of their Immunotherapy growth report which shows increasing cases of allergies and inefficient treatment methods.
Online PR News – 02-December-2020 – SHENZHEN – Immunother Limited’s research team identified methods such as pharmacotherapy for controlling the occurrence rate of allergies and allergy immunotherapy, which is widely considered as a designated cure for various types of allergies.
Immunother Limited are researching and developing new treatments to cure allergies and the global allergy Immunotherapy market is expected to grow considerably over the next 5 years.
Immunother Limited’s Director, Mr. Lin Zhang PhD, commented on the report saying “We have given immunotherapy market a very positive outlook for the future and we strongly believe the global allergy immunotherapy market is poised to exceed US$ 3.5 billion by 2025 with an impressive CAGR growth of over 15 percent.”
“Our dedicated research and reports show the growing focus on taking preventive measures against chronic illnesses is also a catalyst for growth in the allergy immunotherapy market. Around 50 million people suffer from various types of allergies every year and it is estimated that by the end of 2025, about half of the population will suffer from some type of allergic diseases,” added Lin Zhang, Director of Immunother Limited.
About Us - Immunother Limited
Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.